Adverse events associated with dasatinib in the total population (n = 186) at 8-months' follow-up
| Nonhematologic toxicity* . | All grades . | Grades 3 to 4 . |
|---|---|---|
| Headache | 63 (34) | 2 (1) |
| Diarrhea | 56 (30) | 4 (2) |
| Fatigue | 52 (28) | 2 (1) |
| Dyspnea | 51 (27) | 6 (3) |
| Rash | 41 (22) | 1 (0.5) |
| Asthenia | 37 (20) | 3 (2) |
| Nausea | 36 (19) | 2 (1) |
| Pleural effusion | 35 (19) | 6 (3) |
| Peripheral edema | 33 (18) | 0 (0) |
| Serum chemistry | ||
| Elevated bilirubin | 26 (14) | 0 (0) |
| Elevated activity of ALAT | 96 (52) | 3 (2) |
| Elevated activity of ASAT | 111 (60) | 4 (2) |
| Cytopenias grade 3 to 4 | ||
| Leukocytopenia | NA | 46 (25) |
| Neutropenia | NA | 92 (49) |
| Thrombocytopenia | NA | 88 (47) |
| Anemia | NA | 40 (22) |
| Nonhematologic toxicity* . | All grades . | Grades 3 to 4 . |
|---|---|---|
| Headache | 63 (34) | 2 (1) |
| Diarrhea | 56 (30) | 4 (2) |
| Fatigue | 52 (28) | 2 (1) |
| Dyspnea | 51 (27) | 6 (3) |
| Rash | 41 (22) | 1 (0.5) |
| Asthenia | 37 (20) | 3 (2) |
| Nausea | 36 (19) | 2 (1) |
| Pleural effusion | 35 (19) | 6 (3) |
| Peripheral edema | 33 (18) | 0 (0) |
| Serum chemistry | ||
| Elevated bilirubin | 26 (14) | 0 (0) |
| Elevated activity of ALAT | 96 (52) | 3 (2) |
| Elevated activity of ASAT | 111 (60) | 4 (2) |
| Cytopenias grade 3 to 4 | ||
| Leukocytopenia | NA | 46 (25) |
| Neutropenia | NA | 92 (49) |
| Thrombocytopenia | NA | 88 (47) |
| Anemia | NA | 40 (22) |
Results shown as number (%).
ALAT indicates alanine aminotransferase; ASAT, aspartate aminotransferase; and NA, not applicable.
Nonhematologic adverse events experienced by ≥10% of patients.